Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONeeR: Precision Immuno-Oncology in Advanced NSCLC
NCT03833440Phase 2Active, not recruiting
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Oct 2019
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, monalizumab, oleclumab, ceralasertib, savolitinib in non-small cell lung cancer (NSCLC), sponsored by Assistance Publique-Hôpitaux de Marseille. Started Oct 2019; status: active, not recruiting.
02
Drugs
durvalumabmonalizumaboleclumabceralasertibsavolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03833440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833440.